Juan Alberto Piñero-Fernández1, Carmen Vicente-Calderón2, María José Lorente-Sánchez2, María Jesús Juan-Fita3, José María Egea-Mellado3, Inmaculada C González-Gallego3. 1. Pediatric Nephrology Department, Hospital Clínico Universitario Virgen de La Arrixaca, Carretera Madrid-Cartagena S/N, 30120, Murcia, Spain. juanalberto.pinero@carm.es. 2. Pediatric Nephrology Department, Hospital Clínico Universitario Virgen de La Arrixaca, Carretera Madrid-Cartagena S/N, 30120, Murcia, Spain. 3. Metabolic Diseases Unit, Centro de Bioquímica y Genética Clínica, Hospital Universitario Virgen de La Arrixaca, Murcia, Spain.
Abstract
BACKGROUND: Cystinuria is an inherited metabolic disease involving the defective transport of cystine and the dibasic amino acids in the renal proximal tubules that causes the formation of stones in the urinary system. In our regional child health program, cystinuria is included in newborn metabolic screening. Our objectives are the phenotypic characterization of our cystinuric pediatric cohort and to present our experience in neonatal cystinuria screening. METHODS: The study of clinical cases of pediatric patients diagnosed with cystinuria over a period of 32 years. All patients were studied at demographic, clinical, laboratory, radiological, and therapeutic levels. RESULTS: We diagnosed 86 pediatric patients with cystinuria; 36% of them had the homozygous biochemical phenotype. 95.3% of the patients were detected by neonatal metabolic screening. We performed urine biochemical analyses of parents with additional diagnoses of 63 adult patients. The mean follow-up time was 16.8 ± 8.5 years. 11.6% of patients developed one or more episodes of urinary tract infection during that period. Chronic kidney disease, proteinuria, and hypertension were uncommon (1.2%). 10.5% developed kidney stones at the mean age of presentation of 7.78 ± 7.6 years; 33% were recurrent. The risk of developing lithiasis was higher for homozygous biochemical-phenotype patients. Hypercalciuria was a significant risk factor in the development of lithiasis. CONCLUSIONS: Our clinical data suggest that diagnosing cystinuria through neonatal screening could be a useful strategy for the detection of presymptomatic cases, in order to establish preventive measures, as well as for the detection of relatives at risk. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Cystinuria is an inherited metabolic disease involving the defective transport of cystine and the dibasic amino acids in the renal proximal tubules that causes the formation of stones in the urinary system. In our regional child health program, cystinuria is included in newborn metabolic screening. Our objectives are the phenotypic characterization of our cystinuric pediatric cohort and to present our experience in neonatal cystinuria screening. METHODS: The study of clinical cases of pediatric patients diagnosed with cystinuria over a period of 32 years. All patients were studied at demographic, clinical, laboratory, radiological, and therapeutic levels. RESULTS: We diagnosed 86 pediatric patients with cystinuria; 36% of them had the homozygous biochemical phenotype. 95.3% of the patients were detected by neonatal metabolic screening. We performed urine biochemical analyses of parents with additional diagnoses of 63 adult patients. The mean follow-up time was 16.8 ± 8.5 years. 11.6% of patients developed one or more episodes of urinary tract infection during that period. Chronic kidney disease, proteinuria, and hypertension were uncommon (1.2%). 10.5% developed kidney stones at the mean age of presentation of 7.78 ± 7.6 years; 33% were recurrent. The risk of developing lithiasis was higher for homozygous biochemical-phenotype patients. Hypercalciuria was a significant risk factor in the development of lithiasis. CONCLUSIONS: Our clinical data suggest that diagnosing cystinuria through neonatal screening could be a useful strategy for the detection of presymptomatic cases, in order to establish preventive measures, as well as for the detection of relatives at risk. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: Hannah L Rhodes; Laura Yarram-Smith; Sarah J Rice; Ayla Tabaksert; Noel Edwards; Alice Hartley; Mark N Woodward; Sarah L Smithson; Charles Tomson; Gavin I Welsh; Margaret Williams; David T Thwaites; John A Sayer; Richard J M Coward Journal: Clin J Am Soc Nephrol Date: 2015-05-11 Impact factor: 8.237
Authors: M Font-Llitjós; M Jiménez-Vidal; L Bisceglia; M Di Perna; L de Sanctis; F Rousaud; L Zelante; M Palacín; V Nunes Journal: J Med Genet Date: 2005-01 Impact factor: 6.318
Authors: Thomas Knoll; Antonia Zöllner; Gunnar Wendt-Nordahl; Maurice Stephan Michel; Peter Alken Journal: Pediatr Nephrol Date: 2004-11-25 Impact factor: 3.714
Authors: Aude Servais; Kay Thomas; Luca Dello Strologo; John A Sayer; Soumeya Bekri; Aurelia Bertholet-Thomas; Matthew Bultitude; Giovanna Capolongo; Rimante Cerkauskiene; Michel Daudon; Steeve Doizi; Valentine Gillion; Silvia Gràcia-Garcia; Jan Halbritter; Laurence Heidet; Marleen van den Heijkant; Sandrine Lemoine; Bertrand Knebelmann; Francesco Emma; Elena Levtchenko Journal: Kidney Int Date: 2020-09-09 Impact factor: 10.612